Last reviewed 2026-05-15 · How we verify

Afatinib, Osimertinib, Carboplatin and Pemetrexed

Afatinib, Osimertinib, Carboplatin and Pemetrexed is a Tyrosine kinase inhibitor, Platinum-based chemotherapy, Antifolate Small molecule drug developed by Amsterdam UMC, location VUmc. It is currently in Phase 2 development for Non-small cell lung cancer, Squamous non-small cell lung cancer, Non-small cell lung cancer with EGFR exon 19 deletion or exon 21 L858R mutation, Malignant pleural mesothelioma.

Afatinib and Osimertinib are irreversible tyrosine kinase inhibitors targeting the epidermal growth factor receptor (EGFR), while Carboplatin is a platinum-based chemotherapy drug that works by crosslinking DNA, and Pemetrexed is an antifolate drug that inhibits thymidylate synthase.

Afatinib and Osimertinib are irreversible tyrosine kinase inhibitors targeting the epidermal growth factor receptor (EGFR), while Carboplatin is a platinum-based chemotherapy drug that works by crosslinking DNA, and Pemetrexed is an antifolate drug that inhibits thymidylate synthase. Used for Non-small cell lung cancer, Squamous non-small cell lung cancer, Non-small cell lung cancer with EGFR exon 19 deletion or exon 21 L858R mutation, Malignant pleural mesothelioma.

At a glance

Mechanism of action

Afatinib and Osimertinib specifically target the EGFR tyrosine kinase domain, leading to the inhibition of tumor cell proliferation. Carboplatin forms platinum-DNA adducts, which interfere with DNA replication and transcription, ultimately leading to cell death. Pemetrexed inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase, which are essential for DNA synthesis and repair.

Approved indications

• Non-small cell lung cancer, Squamous non-small cell lung cancer, Non-small cell lung cancer with EGFR exon 19 deletion or exon 21 L858R mutation
• Malignant pleural mesothelioma

Common side effects

• Diarrhea
• Nausea
• Vomiting
• Fatigue
• Rash
• Anemia
• Neutropenia
• Thrombocytopenia
• Anorexia
• Weight loss

Key clinical trials

• Combining Afatinib and Concurrent Chemotherapy, Followed by Osimertinib and Concurrent Chemotherapy, in Untreated EGFR Positive NSCLC Tumors (PHASE2)
• PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Afatinib, Osimertinib, Carboplatin and Pemetrexed CI brief — competitive landscape report
• Afatinib, Osimertinib, Carboplatin and Pemetrexed updates RSS · CI watch RSS
• Amsterdam UMC, location VUmc portfolio CI

Frequently asked questions about Afatinib, Osimertinib, Carboplatin and Pemetrexed

Related

• Drug class: All Tyrosine kinase inhibitor, Platinum-based chemotherapy, Antifolate drugs
• Target: All drugs targeting EGFR, DNA
• Manufacturer: Amsterdam UMC, location VUmc — full pipeline
• Therapeutic area: All drugs in Oncology
• Indication: Drugs for Non-small cell lung cancer, Squamous non-small cell lung cancer, Non-small cell lung cancer with EGFR exon 19 deletion or exon 21 L858R mutation
• Indication: Drugs for Malignant pleural mesothelioma
• Compare: Afatinib, Osimertinib, Carboplatin and Pemetrexed vs similar drugs
• Pricing: Afatinib, Osimertinib, Carboplatin and Pemetrexed cost, discount & access